Impact of Coronavirus Disease 2019 Pandemic on Parkinson's Disease: A Cross-Sectional Survey of 568 Spanish Patients

Diego Santos-García, Mila Oreiro, Patricia Pérez, Gemma Fanjul, Jose Manuel Paz González, María José Feal Painceiras, Carlos Cores Bartolomé, Lorena Valdés Aymerich, Carlos García Sancho, Maria Del Mar Castellanos Rodrigo, Diego Santos-García, Mila Oreiro, Patricia Pérez, Gemma Fanjul, Jose Manuel Paz González, María José Feal Painceiras, Carlos Cores Bartolomé, Lorena Valdés Aymerich, Carlos García Sancho, Maria Del Mar Castellanos Rodrigo

Abstract

Background: The aim of this study was to know the impact of the coronavirus disease 2019 (COVID-19) pandemic on Spanish patients with Parkinson's disease (PD).

Methods: This is a descriptive, observational, cross-sectional study. An anonymous online survey with 95 questions was distributed among patients. Responses were collected from 11 May 2020 to 20 July 2020.

Results: Of a total of 570 questionnaires received, 568 (99.6%) were considered valid for the analysis (mean age, 63.5 ± 12.5 years; 53% females). A total of 553 patients (97.4%) were aware of the COVID-19 pandemic and 68.8% were concerned about it; 95.6% took preventive measures. A total of 484 patients (85.2%) had no contact with cases of COVID-19, and only 15 (2.6%) had confirmed COVID-19. Although up to 72.7% remained active during confinement, 65.7% perceived a worsening of their symptoms.

Conclusions: Spanish patients with PD perceived the COVID-19 pandemic with concern and responsibility. More than half experienced worsening of their symptoms during confinement. © 2020 International Parkinson and Movement Disorder Society.

Keywords: COVID-19; Parkinson's disease; confinement; impact; pandemic.

© 2020 International Parkinson and Movement Disorder Society.

References

    1. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and coronavirus disease‐2019 (COVID‐19): the epidemic and the challenges. Int J Antimicrob Agents 2020;55:105924.
    1. Helmich RC, Bloem BR. The impact of the COVID‐19 pandemic on Parkinson's disease: hidden sorrows and emerging opportunities. J Parkinsons Dis 2020;10:351–354.
    1. Koo JR, Cook AR, Park M, et al. Interventions to mitigate early spread of SARS‐CoV‐2 in Singapore: a modelling study. Lancet Infect Dis 2020;10:677–688.
    1. Prem K, Liu Y, Russell TW, et al. The efect of control strategies to reduce social mixing on outcomes of the COVID‐19 epidemic in Wuhan, China: a modelling study. Lancet Public Health 2020;5:261–270.
    1. Haybar H, Kazemnia K, Rahim F. Underlying chronic disease and COVID‐19 infection: a state‐of‐the‐art review. Jundishapur J Chronic Dis Care 2020;9:e103452.
    1. Stoessl AJ, Bhatia KP, Merello M. Movement disorders in the world of COVID‐19. Mov Disord Clin Pract 2020;74:355–356.
    1. Papa SM, Brundin P, Fung VSC, et al. Impact of the COVID‐19 pandemic on Parkinson's disease and movement disorders. Mov Disord Clin Pract 2020;7:357–360.
    1. Moro E, Fernandez HH. Adaptive neurology in COVID‐19 times. Parkinsonism Relat Disord 2020;30168‐1:S1353–S8020.
    1. Prasad S, Holla VV, Neeraja K, et al. Parkinson's disease and COVID‐19: perceptions and implications in patients and caregivers. Mov Disord 2020;35:912–914.
    1. Salari M, Zali A, Ashrafi F, et al. Incidence of anxiety in Parkinson's disease during the coronavirus disease (COVID‐19) pandemic. Mov Disord 2020;35:1095–1096.
    1. Zipprich HM, Teschner U, Witte OW, Schönenberg A, Prell T. Knowledge, attitudes, practices, and burden during the COVID‐19 pandemic in people with Parkinson's disease in Germany. J Clin Med 2020;9(6):E1643.
    1. Schirinzi T, Cerroni R, Di Lazzaro G, et al. Self‐reported needs of patients with Parkinson's disease during COVID‐19 emergency in Italy. Neurol Sci 2020;41:1373–1375.
    1. Bhidayasiri R, Virameteekul S, Kim JM, Pal PK, Chung SJ. COVID‐19: an early review of its global impact and considerations for Parkinson's disease patient Care. J Mov Disord 2020;13:105–114.
    1. Ahorsu DK, Lin CY, Imani V, Saffari M, Griffiths MD, Pakpour AH. The fear of COVID‐19 scale: development and initial validation. Int J Ment Health Addict 2020;1–9.
    1. Zach H, Dirkx MF, Pasman JW, Bloem BR, Helmich RC. Cognitive stress reduces the effect of levodopa on Parkinson's resting tremor. CNS Neurosci Ther 2017;23:209–215.
    1. The Michael J. Fox Foundation for Parkinson's Research. .
    1. van der Kolk NM, de Vries NM, Kessels RPC, et al. Effectiveness of home‐based and remotely supervised aerobic exercise in Parkinson's disease: a double‐blind, randomised controlled trial. Lancet Neurol 2019;18:998–1008.
    1. Srivastav AK, Asir JS. E‐rehabilitation: one solution for patients with Parkinson's disease in COVID‐19 era. Parkinsonism Relat Disord 2020;75:128–129.
    1. Fasano A, Antonini A, Katzenschlager R, et al. Management of advanced therapies in Parkinson's disease patients in times of humanitarian crisis: the COVID‐19 experience. Mov Disord Clin Pract 2020;7:361–372.
    1. Goetz CG, Stebbins GT, Luo S. Movement Disorder Society‐unified Parkinson's disease rating scale use in the Covid‐19 era. Mov Disord 2020;35(6):911.
    1. Miocinovic S, Ostrem JL, Okun MS, et al. Recommendations for deep brain stimulation device management during a pandemic. J Parkinsons Dis 2020;10:903–910.
    1. Cubo E, Hassan A, Bloem BR, Mari Z, MDS‐Telemedicine Study Group . Implementation of telemedicine for urgent and ongoing healthcare for patients with Parkinson's disease during the COVID‐19 pandemic: new expectations for the future. J Parkinsons Dis 2020;10:911–913.
    1. Devigili G, Eleopra R, Rinaldo S, Lanteri P. Lessons from the present: intraoperative neurophysiological monitoring organization during the COVID‐19 pandemic in Lombardy, northern Italy. Clin Neurophysiol 2020;131:2056–2058.
    1. Dang S, Penney LS, Trivedi R, et al. Caring for caregivers during COVID‐19. J Am Geriatr Soc 2020; (epub head of print). 10.1111/jgs.16726.
    1. Fasano A, Cereda E, Barichella M, et al. COVID‐19 in Parkinson's disease patients living in Lombardy, Italy. Mov Disord 2020;35:1089–1093.
    1. Cilia R, Bonvegna S, Straccia G, et al. Effects of COVID‐19 on Parkinson's disease clinical features: a community‐based case‐control study. Mov Disord 2020;35:1287–1292.
    1. Tipton PW, Wszolek ZK. What can Parkinson's disease teach us about COVID‐19? Neurol Neurochir Pol 2020;54:204–206.
    1. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;m1091:368.
    1. Hamer M, Kivimäki M, Gale CR, Batty GD. Lifestyle risk factors for cardiovascular disease in relation to COVID‐19 hospitalization: a community‐based cohort study of 387,109 adults in UK. medRxiv 2020. 10.1101/2020.05.09.20096438.
    1. Smieszek SP, Przychodzen BP, Polymeropoulos MH. Amantadine disrupts lysosomal gene expression: a hypothesis for COVID19 treatment. Int J Antimicrob Agents 2020;55:106004.
    1. Rejdak K, Grieb P. Adamantanes might be protective from COVID‐19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Mult Scler Relat Disord 2020;42:102163.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться